Trial · NCT00367744

Rosiglitazone Effect on Mitochondria and Lipoatrophy

NCT00367744, Phase 2, Completed, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2017-02-06

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Rosiglitazone Effect on Mitochondria and Lipoatrophy. Trials, record NCT00367744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00367744

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Rosiglitazone Effect on Mitochondria and Lipoatrophy
NCT number: NCT00367744
Status: Completed
Phases: Phase 2
Enrollment: 71 participants, actual
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions: HIV Infections
Interventions: Rosiglitazone, Placebo
First posted: 2006-08-23
Last updated: 2017-02-06
Results first posted: 2017-02-06
Limitations and caveats: Limitations of the study include a relative small sample size as well as loss of follow up of 9 participants at the end of the study.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Limb Fat at 48 Weeks	48 weeks	Limb fat was measured at baseline and visit week 48 using dual-energy x-ray absorptiometry (DEXA), and change from baseline to week 48 (week 48 - baseline) was estimated for the treatment groups.
Secondary	the Change in the Carotid IMT of the Common Carotid Artery	48 weeks	Carotid IMT of the Common carotid artery (CCA) was measured at baseline and week 48, and change from baseline to week 48 (week 48 - baseline) was estimated for the treatment groups.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Limb Fat at 48 Weeks	48 weeks	Intention to treat analysis with last observation carried forward if week 48 limb fat data was missing and post-baseline limb fat was availble.	grams	MEDIAN
SECONDARY	the Change in the Carotid IMT of the Common Carotid Artery	48 weeks	Intention to treat analysis with last observation carried forward if week 48 carotid IMT data was missing and post-baseline IMT data was available	mm	MEDIAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Limb Fat at 48 Weeks	Rosiglitazone	448	Inter-Quartile Range 138 to 1670	grams
Change in Limb Fat at 48 Weeks	Placebo	153	Inter-Quartile Range -100 to 682	grams
the Change in the Carotid IMT of the Common Carotid Artery	Rosiglitazone	0.10	Inter-Quartile Range -0.05 to 0.25	mm
the Change in the Carotid IMT of the Common Carotid Artery	Placebo	0.15	Inter-Quartile Range 0 to 0.25	mm

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Rosiglitazone	34
Overall Study	STARTED	Placebo	37
Overall Study	COMPLETED	Rosiglitazone	30
Overall Study	COMPLETED	Placebo	32
Overall Study	NOT COMPLETED	Rosiglitazone	4
Overall Study	NOT COMPLETED	Placebo	5

Source ClinicalTrials.gov

Adverse events40

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Low Fasting Glucose (Grade 1)	Metabolism and nutrition disorders	Rosiglitazone	1	34
other	Low Fasting Glucose (Grade 1)	Metabolism and nutrition disorders	Placebo	0	37
other	Low Phosphate (Grade 2)	Musculoskeletal and connective tissue disorders	Rosiglitazone	5	34
other	Low Phosphate (Grade 2)	Musculoskeletal and connective tissue disorders	Placebo	5	37
other	Elevated Bilirubin (Grade 2 or 3)	Blood and lymphatic system disorders	Rosiglitazone	0	34
other	Elevated Bilirubin (Grade 2 or 3)	Blood and lymphatic system disorders	Placebo	1	37
other	Elevated Creatine Kinase (Grade 2)	Musculoskeletal and connective tissue disorders	Rosiglitazone	0	34
other	Elevated Creatine Kinase (Grade 2)	Musculoskeletal and connective tissue disorders	Placebo	1	37
serious	Elevated Cholesterol (Grade 2 or 3)	Cardiac disorders	Rosiglitazone	4	34
serious	Elevated Cholesterol (Grade 2 or 3)	Cardiac disorders	Placebo	6	37

1 to 10 of 40Source ClinicalTrials.gov

See all 40 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Rosiglitazone
Total, all-cause mortality	Placebo
Total, other adverse events	Rosiglitazone	6	34
Total, other adverse events	Placebo	7	37
Total, serious adverse events	Rosiglitazone	15	34
Total, serious adverse events	Placebo	13	37

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
20453626	DERIVED	PubMed
20969457	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Rosiglitazone vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00367744

GET https://conductscience.org/api/trials/v1/NCT00367744/events?page=2

API reference For AI assistants